Long-Term Follow-up of the West of Scotland Coronary Prevention Study

• Published in: The New England journal of medicine Vol. 357; no. 15; pp. 1477 - 1486
• Main Authors: Ford, Ian, Murray, Heather, Packard, Chris J, Shepherd, James, Macfarlane, Peter W, Cobbe, Stuart M
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 11.10.2007
• Subjects: Anticholesteremic Agents - therapeutic use; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular disease; Cholesterol; Coronary Disease - mortality; Coronary Disease - prevention & control; Coronary heart disease; Drug therapy; Follow-Up Studies; General aspects; Heart; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - drug therapy; Kaplan-Meier Estimate; Male; Medical sciences; Middle Aged; Myocardial Infarction - epidemiology; Myocardial Infarction - prevention & control; Pravastatin - therapeutic use; United Kingdom; Scotland; Great Britain; Europe; United Kingdom > UK; Medicine; Prevention; West; Coronary artery; Cardiovascular disease; Coronary heart disease; Long term
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa065994

The West of Scotland Coronary Prevention Study demonstrated a significant reduction in coronary events after 5 years of treatment with pravastatin as compared with placebo. Participants were followed for an additional 10 years; approximately one third used statins. The rate of coronary events was reduced by 27% over the entire follow-up interval. This long-term follow-up of patients treated with pravastatin showed that the rate of coronary events was reduced by 27% over the entire follow-up interval. The West of Scotland Coronary Prevention Study (WOSCOPS) was a randomized, double-blind, placebo-controlled clinical trial of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin (Pravachol, Bristol-Myers Squibb) in middle-aged men without a history of myocardial infarction. 1 – 3 After an average of approximately 5 years, the combined outcome of death from definite coronary heart disease or definite nonfatal myocardial infarction was reduced from 7.9% in the placebo group to 5.5% in the pravastatin group (P<0.001), and the risk of death from definite or suspected coronary heart disease was reduced from 1.9% to 1.3% (P=0.04). There was a trend toward a reduction in . . .